555: Two Worlds, One Career | Mike Kaseta, CFO, Aerami Therapeutics December 11, 2019 Continue Reading
Aerami Therapeutics to Present Clinical Data on Dance 501 Inhaled Human Insulin at the 19th Diabetes Technology Meeting November 11, 2019 Continue Reading
The Promise of More Effective Inhaled Endocrine-Focused Therapeutics October 8, 2019 Continue Reading
Drug company’s Bay Area exodus: All about a new CEO, the right talent — and getting out of founder’s living room September 27, 2019 Continue Reading
Dance Biopharm Announces Rebranding to Aerami Therapeutics Reflecting a Broadened Strategic Focus on Inhaled Therapies for Chronic Diseases September 25, 2019 Continue Reading
